Since both FLT3–ITD and FLT3–TKD mutations promote constitutive FLT3 kinase activity, sustaining leukemic cell proliferation and survival, gilteritinib-mediated inhibitory effects have the potential to lessen the leukemia burden of AML patients (Figure 1). Here, FLT3 is linked to leukemia.